DCDC2 and neoplasm: In vivo assays revealed that treatment with Lag-3 antibodies negated the tumor growth enhancement associated with Dcdc2 overexpression, while Fgl1 knockdown blocked the efficacy of Lag-3 antibodies (Fig. 8F, G, H and Supplementary Fig. 8E).